Conference Proceedings
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, Rodney J Hicks, Besiat Birbirsa, Mathias Bressel, Juliana Di Iulio, David Alan Westerman, Stephen Lade, Rishu Agarwal, Mark A Dawson, Sarah-Jane Dawson, Rachel Koldej, David Ritchie, John F Seymour, Andrew W Roberts, Constantine S Tam
BLOOD | AMER SOC HEMATOLOGY | Published : 2019
Abstract
Background: The phase II AIM trial (Tam et al, NEJM 2018; NCT02471391), using combination BTK inhibitor ibrutinib (IB) and BCL-2 inhibitor venetoclax (VEN) therapy achieved excellent 16 week complete remission rates (CRR) (primary endpoint; 62%) in patients (pts) with poor prognosis mantle cell lymphoma (MCL), higher than currently approved second line IB monotherapy. Additionally, overall response rate (ORR) by PET of 71%, with attainment of minimal residual disease (MRD) negativity was reported. At the time of primary endpoint analysis (median follow up 15.9 months), median progression free survival (PFS), duration of response (DOR), time to progression (TTP) and overall survival (OS) had ..
View full abstract